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ABSTRACT Previously, a modiﬁed HIV Env protein with a heterologous membrane anchor was found to be incorporated into
HIVvirus-likeparticles(VLPs)at10-fold-higherlevelsthanthoseofunmodiﬁedEnv.Tofurtherimprovetheimmunogenicity
ofsuchVLPs,membrane-anchoredformsofbacterialﬂagellin(FliC)oraﬂagellinwithatruncatedvariableregion(tFliC)were
constructedtobeincorporatedintotheVLPsasadjuvants.HIV-speciﬁcimmuneresponsesinducedbytheresultingVLPswere
determinedinaguineapigmodel.TheVLPsinduceenhancedsystemicantibodyresponsesbyeithersystemicormucosalvacci-
nationandenhancedmucosalimmunitybyamucosalimmunizationroute,asdemonstratedbyhighlevelsofHIV-speciﬁcse-
rumIgGandmucosalIgGandIgA.Thequalityoftheantibodyresponseswasalsoimproved,asshownbyenhancedneutraliza-
tioncapacity.VLPsincorporatingFliCweremoreeffectiveininducingsystemicresponses,whileVLPscontainingtFliCwere
moreeffectiveininducingmucosalIgAresponses.TheIgGtitersinserawerefoundtolastforatleast5monthswithoutasigniﬁ-
cantdrop.TheseresultsindicatethatHIVVLPsincorporatinghighlevelsofEnvandamolecularadjuvanthaveexcellentpoten-
tialforfurtherdevelopmentasaprophylacticHIVvaccine.
IMPORTANCE AprophylacticvaccineisurgentlyneededtocontrolthespreadofHIV/AIDS.Antigensinducingstrongsystemic
andmucosalimmuneresponsesarepromisingasvaccinesforthismucosallytransmitteddisease.WefoundthatnovelHIV
virus-likeparticles(VLPs)presentingahighlevelofEnvinitsnativemembrane-boundformandcoincorporatinganinnate
immune-signalingadjuvantinthesameparticleswereeffectiveininducingenhancedsystemicandmucosalimmunity.Asnew
HIVvaccinecandidates,theseVLPsbridgethegapsoftheinnateandadaptive,aswellassystemicandmucosal,immunere-
sponses,providinganewapproachforHIVvaccinedevelopment.
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H
uman immunodeﬁciency virus type 1 (HIV-1) has infected
over 60 million individuals, resulting in acquired immuno-
deﬁciency syndrome (AIDS), and has caused the death of over 20
millionpeopleworldwidesinceitsdiscoveryastheetiologicagent
ofAIDS(1).Thedevelopmentofaprophylacticvaccinewouldbe
the most effective measure to curb this fatal AIDS pandemic. Al-
thoughpreviousclinicaltrialsofHIVvaccineshavefailed,arecent
trial conducted in Thailand reported a modest ability (around
30%) to protect from HIV by a combined vaccination strategy,
indicatingthepossibilityofaprophylacticvaccineandtheimpor-
tance of further studies (2).
A prophylactic HIV-1 vaccine should elicit effective antibody
responses, including broadly cross-reactive neutralizing activity
(3–5). The gp120-gp41 Env protein on the native virion is the
primary target for eliciting such antibodies. Recent studies dem-
onstrated that effective antibodies even at lower titers can protect
against low-dose repeated mucosal simian/human immunodeﬁ-
ciency virus (SHIV) challenge in macaques, which mimics infec-
tion of humans by sexual contact (6). This ﬁnding supports the
importantpotentialroleofmucosalantibodyinprotectiveimmu-
nity. Progress has been achieved in recent years in enhancing the
immunogenicity of Env by modifying its structure, employing
noveldeliveryplatforms,andcoadministeringofadjuvants(7–9).
Theuseofvirus-likeparticles(VLPs)hasshowngreatpotentialas
a new vaccine platform (10–14). Such VLPs present the Env pro-
tein in its native membrane-bound form and have a high level of
safety because they lack the viral genome.
Flagellin is the primary protein component of the highly com-
plex ﬂagellar structures that extend from the outer membrane of
Gram-negative organisms. It is known that Toll-like receptor 5
(TLR5) recognizes a conserved site on ﬂagellin (15). Acting as the
natural agonist of TLR5, ﬂagellin was found to be a highly potent
and effective adjuvant in humans and nonhuman primates (16–
18).Theadjuvanteffectsofﬂagellinforantibodyresponses,aswell
as T cell responses, have been demonstrated for puriﬁed natural,
recombinant, and truncated forms (19–22). Removal of the vari-
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innate immunity while decreasing the antigenicity of ﬂagellin
(23). Here we investigated whether the immunogenicity of HIV
VLPs can be enhanced by incorporation of a membrane-bound
formofﬂagellinoraﬂagellinwithatruncatedvariableregionasan
adjuvant for induction of both systemic and mucosal antibody
responses.
RESULTS
Construction of membrane-anchored forms of full-length
ﬂagellinandﬂagellinwithatruncatedvariableregion. Inapre-
vious study, we found that a modiﬁed form of HIV-1 Env with
heterologoustransmembrane/cytoplasmic(TM/CT)domainsde-
rivedfromthemousemammarytumorvirus(MMTV)glycopro-
tein was incorporated into Gag-derived HIV-1 VLPs at 10- to
15-fold-higherlevelsthannativeEnv(24).Inthepresentstudy,we
determine whether coincorporation of a membrane-anchored
ﬂagellin, the Toll-like receptor 5 (TLR5) ligand, into such VLPs
willinduceenhancedantibodyresponsesandneutralizationreac-
tivity.Thus,weconstructedgenesencodingmembrane-anchored
ﬂagellin (FliC), as depicted in Fig. 1A. We also constructed a
membrane-anchored ﬂagellin with a truncated variable region
(tFliC) because the soluble truncated protein was reported to be
more effective as a mucosal adjuvant (23). The N-terminal do-
main 1 and 2 (ND1-2; amino acids [aa] 1 to 176) and C-terminal
domain 2 and 1 (CD2-1; aa 402 to 459) sequences corresponding
to the full-length Salmonella enterica serovar Typhimurium
ﬂagellin-encoding DNA were fused by overlapping PCR with a
hinge region to enhance the ﬂexibility for the terminal sequences
ofﬂagellintoformthenecessaryconformationforTLR5recogni-
tion (21). The mellitin signal peptide (SP) and MMTV TM/CT
domain-encoding sequences were used in the membrane-
anchored ﬂagellin constructs because they were found to result in
a higher incorporation of modiﬁed HIV Env protein into VLPs
(24). The resulting chimeric ﬂagellin genes were used to generate
recombinant baculoviruses (rBVs) expressing membrane-
anchored ﬂagellin in insect cells.
Characterization of HIV-1 cVLPs containing high levels of
Env and membrane-anchored ﬂagellin. Standard and chimeric
HIVVLPs(cVLPs)wereproducedbyrBVexpressionasdescribed
inMaterialsandMethods.Ourhypothesisisthatincorporationof
the antigen (Env) and the adjuvant into the same cVLP structure,
as schematized in Fig. 1B, will deliver both components to the
same cells and thus be advantageous for enhancing immunoge-
nicity. The protein composition of VLPs was characterized by
Westernblotting,asshowninFig.1C.Asdescribedpreviously,the
modiﬁed Con-S Env is a derivative of Con-S gp145CFI (25),
with heterologous TM/CT domains from the MMTV Env glyco-
proteintoenhanceincorporationintoVLPsathighlevels(24).As
showninFig.1C,themodiﬁedEnvincorporatedintostandardor
cVLPs was observed to have a molecular mass of about 120 kDa.
This is lower than expected for mammalian cell expression
(145kDa),probablybecauseofadifferentglycosylationpatternin
insect cells. Quantitative analysis showed that these VLPs con-
tained up to 16 g of Env per 100 g of VLPs, which is similar to
thepreviouslyobservedincorporationlevel(24).Themembrane-
anchored ﬂagellin is predicted to have a molecular mass of about
60 kDa. Western blotting showed protein bands around 60 kDa,
but with isoforms, suggesting nonuniform glycosylation. These
results are consistent with our previous observation that a
membrane-anchored form of ﬂagellin had a nonuniform glyco-
sylation pattern in insect cells (12). Multiple bands also were ob-
servedforthemembrane-anchoredtruncatedﬂagellin(molecular
mass of approximately 39 kDa), for which the Western blot
showed two bands detected by ﬂagellin-speciﬁc antibody. The in-
corporation levels of ﬂagellin into VLPs (ranging from 1 to 2 g/
100 g of VLPs in different preparations) can be regulated by
varying the multiplicity of infection (MOI) of the rBV used for
expression.
HIV-1 cVLPs induce high titers of Env-speciﬁc antibody. As
shown in Fig. 2, cVLPs containing membrane-anchored ﬂagellin
administeredeitherintramuscularly(i.m.)orintranasally(i.n.)in
guinea pigs induced serum antibody responses with higher titers
than those observed with standard VLPs. After three immuniza-
tions (bleed 3 in Fig. 2A), guinea pigs immunized i.m. with
ﬂagellin-containing VLPs (Env/Gag/FliC cVLPs) achieved 36-
fold-higher IgG levels (endpoint titer, 1.8  105) than a standard
VLPgroup(5103).ThetFliC-containinggroup(Env/Gag/tFliC
cVLPs) also exhibited 11-fold-higher IgG levels (5.4  104) than
the standard VLP group. Data in Fig. 2B demonstrate that HIV-1
FIG1 SchematicdiagramsofﬂagellinconstructsandcharacterizationofHIV
cVLP. (A) Flagellin constructs. Soluble monomeric ﬂagellin contains
459 amino acid (aa) residues. The N-terminal (ND1-2; aa 1 to 176) and
C-terminal (CD2-1; aa 402 to 459) domains contain motifs that are necessary
forTLR5recognition.Themembrane-anchoredﬂagellin(FliC)constructwas
generated by fusing the mellitin signal peptide, ﬂagellin, and MMTV trans-
membrane/cytoplasmic domain-encoding sequences by overlapping PCR.
The membrane-anchored, FliC construct with a truncated variable region
(tFliC) was formed by replacement of the variable region sequence (corre-
spondingtoaa177to401infull-lengthﬂagellin)withaﬂexiblehingebyusing
overlappingPCR.(B)DiagramofHIV-1cVLP.Envandmembrane-anchored
ﬂagellin (FliC) are both anchored in the envelope. The Gag protein is assem-
bled as a core inside the VLPs during the budding process. (C) Western blot
characterizingEnv,Gag,andﬂagellincomponentsinHIVVLPs.VLPsamples
(1 g) were resolved by SDS-PAGE followed by Western blotting. Env bands
werevisualizedbygoatanti-gp120polyclonalantibody(top);Gagbandswere
detected by HIV-positive human sera; ﬂagellin bands were visualized with
mouse anti-ﬂagellin polyclonal antibody. Lane 1, Gag-only VLPs; lane 2, Env/
Gag VLPs; lane 3, Env/Gag/FliC cVLPs; lane 4, Env/Gag/tFliC cVLPs.
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zation. FliC- and tFliC-containing cVLPs elicited 14- and 8-fold-
higher serum IgG titers (4.5  104 and 2.7  104, respectively)
thanastandardVLPgroup(3103).Incontrast,similaramounts
of soluble ﬂagellin did not show any adjuvant effect when mixed
with standard VLPs prior to i.m. immunization, but induced
slightly enhanced serum antibody responses by i.n. immuniza-
tion. These results indicated that incorporation of the ﬂagellin
moleculesintotheVLPsismuchmoreeffectiveinenhancinganti-
Env immune responses than addition of soluble ﬂagellin to stan-
dard VLPs. Although ﬂagellin-containing VLPs induced en-
hancedIgGresponses,wedidnotdetectIgAimmuneresponsesin
the sera of immunized animals.
We also evaluated the serum IgG subclass proﬁles in bleed 3
and observed that standard VLPs induced IgG2-dominant im-
mune responses, while the FliC-containing cVLPs enhanced both
IgG1 and IgG2 production when administered i.m. (Fig. 3A),
demonstrating that a balanced antibody proﬁle is induced by
cVLPs. In contrast, both full-length cVLPs and cVLPs containing
ﬂagellin with the variable region deleted as well as standard VLPs
induced IgG2-dominant antibody responses (Fig. 3A), but IgG1
levels were undetectable when guinea pigs were vaccinated by the
i.n. route, indicating different effects of ﬂagellin when adminis-
tered i.n. and i.m. It is desirable for vaccine-induced immune
responsestopersistforaprolongedperiodafterimmunization.As
shown in Fig. 3B, serum IgG titers were high after three immuni-
zations (bleed 3) and remained at similar levels for 5 months
(bleed 4). An additional boost immunization did not raise the
responselevelsanyfurther(bleed5).Thesedatademonstratethat
ﬂagellin-containing cVLPs are effective in inducing long-lasting
immune responses.
HIV-1 cVLPs induce enhanced neutralizing reactivity. The
above data demonstrate that HIV-1 cVLPs induce signiﬁcantly
higher titers of serum IgG compared to standard VLPs by either
the i.m. or i.n. immunization route. We further compared the
resulting immune sera for neutralizing infection by a panel of
HIV-1pseudoviruses,usingahigh-throughput,pseudotypevirus
assay system. Five type B viruses, including two tier 1 and two tier
2 strains and one intermediate strain, were compared in the neu-
tralizingantibodyassay.Theircoreceptorsandneutralizationsen-
FIG 2 Flagellin-containing HIV-1 cVLPs induce enhanced systemic immune
responses. Guinea pigs (four animals per group) were immunized with the
indicatedVLPseitherintramuscularly(IM;A)orintranasally(IN;B)atweeks
0, 4, and 8, respectively. Serum IgG endpoint titers were assayed as described
previously(12).Maxisorb96-wellplateswerecoatedwithpuriﬁedHis-tagged
Env (Con-S gp120; 100 ng per well) puriﬁed from HeLa cells infected with a
recombinantvacciniavirus(rVV)expressingEnvgp120.SerumIgGendpoint
titers were measured at week 2 (bleeding 1), week 6 (bleeding 2), and week 10
(bleeding 3). Results are expressed as geometric mean titers with 95% conﬁ-
dence intervals. Triangles and stars indicate statistically signiﬁcant differences
between the FliC- or tFliC-containing VLP groups and the standard VLP
group (P  0.05 by Student’s t test) in bleeds 2 and 3, respectively. G, Gag
VLPs; E/G, Env/Gag VLPs; E/G/tF, Env/Gag/tFliC cVLPs; E/G/F, Env/Gag/
FliC cVLPs; E/G  sF, Env/Gag VLPs plus soluble ﬂagellin.
FIG3 IgGsubclassesanddurationofantibodyresponsesinducedbyﬂagellin-
containingcVLPs.(A)EndpointtitersofIgG1andIgG2.ForIgGisotyping,the
endpoint ELISA was performed as above, except that HRP-conjugated goat
anti-guineapigIgG1orIgG2secondaryantibodies(ImmunologyConsultants
Laboratory, Newburg, OR) were used. Asterisks indicate a statistically signiﬁ-
cant difference (P  0.05) from the Env/Gag group. (B) Duration of antibody
response. Serum IgG endpoint titers at week 10 (bleed 3), week 30 (bleed 4),
and week 43 (bleed 5) were determined as in Fig. 2.
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show that the neutralizing reactivity of the 80-fold-diluted im-
mune sera (20-fold diluted for RHPA4259.7) obtained after the
third immunization varied: standard VLP groups neutralized less
than 20% of the virus infectivity for both i.m. and i.n. immuniza-
tions, except against HXB2 (27.5%) after i.n. immunization
(Fig. 4A and B). FliC-containing cVLPs (Env/Gag/FliC cVLPs) by
i.m. immunization induced the highest neutralization antibody
responses against HXB2, NL4-3, 6535.3, or RHPA4259.7
(Fig.4A).Incontrast,tFliC-containingcVLPs(Env/Gag/tFliCcV-
LPs) were more effective in inducing neutralizing activity against
tier1strains(HXB2andNL4-3)whenadministeredi.n.(Fig.4B).
Wealsoevaluatedthecapacityoftheimmuneseraforneutral-
izingonetier2andoneintermediatetypeCpseudovirus,Du422.1
and Du156.12, as listed in Table 1 (27). We found that immune
sera at a 100-fold dilution after the third immunization (bleed 3)
had no detectable neutralization of Du156.12; sera from groups
immunized with FliC-conaining cVLPs (Env/Gag/FliC cVLPs)
neutralized 45% of Du422.1, while other groups showed much
lower neutralization (less than 20%) against this strain after i.m.
immunization(Fig.4C).Theserafromguineapigsimmunizedby
thei.n.routewithtFliC-containingcVLPs(Env/Gag/tFliCcVLPs)
and FliC-containing cVLPs neutralized 47.5 and 15% of Du422.1
infectivity, respectively, while other groups did not show detect-
able neutralizing activity (Fig. 4D). These results indicate that the
IgGlevelsinseracorrelatewithneutralization.Wealsofoundthat
whensolubleﬂagellinwasmixedwithstandardHIV-1VLPs(Env/
GagVLPsplussFliC),therewasnosigniﬁcantincreaseinneutral-
izingantibodyresponsescomparedtothatwiththestandardVLPs
alone, demonstrating the importance of the physical association
of ﬂagellin with antigens.
HIV-1 cVLPs incorporating tFliC are more effective in in-
ducing mucosal immunity. Mucosal immunization is known to
induce mucosal responses in local, as well as distal mucosal sites
(29,30).Todeterminewhetherﬂagellin-containingcVLPsinduce
strong mucosal immune responses, we evaluated the vaginal mu-
cosal secretory IgA (S-IgA) and IgG levels after i.n. immunization
at week 18 (Fig. 5A and B) and after the last boost at week 38
(Fig. 5C and D). As observed in blood, the highest Env-speciﬁc
IgGlevelinvaginalsecretionswasdetectedintheFliC-containing
cVLP group (compare Fig. 5B and D and Fig. 2). S-IgA proﬁles in
vaginal secretions were, however, different. Remarkably, tFliC-
containing cVLP-immunized guinea pigs showed 20-fold-higher
S-IgAlevelsatweek18(Fig.5A)and60-fold-higherlevelsatweek
38 (Fig. 5C) than standard VLP-immunized guinea pigs. FliC-
containing VLP-immunized guinea pigs showed 2-fold-higher
S-IgA at week 18 and 30-fold-higher S-IgA at week 38 than the
standard VLP group (Fig. 5A versus C), thus demonstrating that
the truncated form of ﬂagellin is a more effective adjuvant for
mucosalimmunization.Inmucosalsamples,thedatascatteringis
intrinsically larger than in sera due to the sample collection pro-
cedure and variations in the estrous cycle. There was a difference
TABLE 1 HIV isolates used for neutralization assays
Isolatea Subtype Coreceptor Sensitivity/resistance to neutralization
HXB2 B CXCR4 Sensitive (tier 1)
NL4-3 B CXCR4 Sensitive (tier 1)
6535.3 B CCR5 Intermediate
RHPA4259.7 B CCR5 Intermediate
Du156.12 C CCR5 Intermediate
Yu2 B CCR5 Resistant (tier 2)
Du422.1 C CCR5 Resistant (tier 2)
a The subtype B and C isolates were arranged in the order of the most-sensitive (tier 1),
intermediate, and most-resistant (tier 2) strains to neutralization from the top to the
bottom of the table.
FIG4 NeutralizationofsubtypeBandCHIV-1strainsbyserafromimmunizedguineapigs.(AandB)Intramuscularly(IM)andintranasally(IN)immunized
groups neutralizing subtype B pseudoviruses. Immune sera (bleed 3) were diluted to 80-fold for assays. For neutralization of RHPA4259.7, serum samples were
diluted to 20-fold. Neutralization assays were performed on JC53-BL cells, a derivative of HeLa cells that express high levels of CD4 and the HIV-1 coreceptors
CCR5 and CXCR4. Infected cells were detected by luciferase activity. (C and D) Intramuscularly and intranasally immunized groups neutralizing a subtype C
pseudovirus, Du422.1. Results are expressed as means  standard deviations (SD).
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tisticallysigniﬁcant.Importantlythesametrend,namelythehigh-
est S-IgA levels in the truncated-ﬂagellin group, was observed in
samples collected at two different time points 143 days apart, de-
spite variations introduced by sample collection and the estrous
cycle phase. These data support the conclusion that the truncated
form of ﬂagellin is a more effective adjuvant for mucosal immu-
nization.
Wefurtherdeterminedwhethermucosalantibodiesconferred
neutralization of infectivity. We used type B tier 1 HXB2
pseudovirus to evaluate the neutralizing activity of the vaginal
samples collected at week 38. As shown in Fig. 5E, vaginal washes
at low dilution from VLP-immunized guinea pigs partially neu-
tralized HXB2. Samples from the standard VLP group had no
detectable neutralization capacity. These results were consistent
with the S-IgA levels in the same vaginal wash samples (Fig. 5C).
We also observed that cVLPs induced ﬂagellin-speciﬁc serum
IgG responses, and tFliC-containing VLPs induced lower re-
sponses than FliC-containing VLPs by either i.m. or i.n. immuni-
zation (data not shown), although it has been known that preex-
isting immunity to ﬂagellin has no effect on its adjuvant function
(12, 17, 31).
DISCUSSION
The design of antigens which are effective in inducing improved
functionalantibodyresponsesisofhighimportanceforAIDSvac-
cine development. Since VLPs are particulate structures which
present trimeric Env proteins in their native membrane-bound
form, they have attractive features as vaccine antigens. We ob-
servedpreviouslythattheEnvincorporationlevelsintoHIVVLPs
canbeimprovedsigniﬁcantlybyengineeringofconstructshaving
heterologous TM/CT domains (24). Here we have shown that by
attaching a membrane anchor sequence from MMTV Env, the
TLR5ligandﬂagellincanalsobeincorporatedasanadjuvantinto
HIVVLPs.Weobservedthattheseﬂagellin-containingVLPselicit
high levels of systemic antibody responses by either i.m. or i.n.
vaccination, as well as both systemic and mucosal immunity by
i.n. vaccination. Chimeric VLPs containing full-length ﬂagellin
were more effective in inducing systemic responses, whereas
cVLPscontainingaﬂagellinwithatruncatedvariableregionwere
more effective in eliciting mucosal IgA responses. We also ob-
served that these cVLPs induced antibody responses with broad
subtypic reactivity.
High antibody responses are expected to be important for a
prophylactic HIV vaccine. Our results demonstrated that anti-
bodybindingtitersagainstgp120weresurprisinglyhigh,reaching
36-fold higher levels than those of the standard VLPs after three
i.m. immunizations with cVLPs containing FliC or 8-fold higher
than those of the standard VLPs after three i.n. immunizations
withcVLPscontainingtFliC.Previousstudieswithsimianimmu-
nodeﬁciency virus (SIV) have also shown that VLPs are highly
immunogenic when antigens and adjuvants are coincorporated
into the same VLP structure (11) or when adjuvant molecules are
chemically conjugated with VLPs (32). The present data demon-
strate the potential of HIV cVLPs incorporating membrane-
anchoredﬂagellinininducingantibodyresponses.Flagellinbinds
to TLR5 and thus not only initiates innate signaling to secrete
cytokines which can upregulate other immune cells, but also fa-
cilitatesDCstotakeupantigensandthenpresentthemtohelperT
cellsinsecondarylymphnodes(33,34).ThesehelperTcellsform
stable cognates with B cells and enhance the ability of B cells to
proliferate and differentiate into plasma B cells (35). It is likely
that the relationship of TLR5 signaling to antigen presentation
could contribute to the enhancement of antibody responses to
HIV VLPs. Because TLR5 is found to be expressed in antigen-
presenting cells (APCs), in particular dendritic cells (DCs), we
have hypothesized that ﬂagellin-containing cVLPs can be
taken-up by APCs after TLR5 binding and promote antigen pre-
sentation because of innate signaling in the same cell (12).
WeobservedthatFliC-containingcVLPsinducedhighertiters
ofbothIgG1andIgG2afteri.m.immunization.Incontrast,tFliC-
containingcVLPsinducedenhancedIgG2titersandundetectable
IgG1levelsafteri.n.immunization.Inguineapigs,theconnection
betweenTh1/Th2responsesandIgGsubclassesisnotestablished,
butthereareindicationsthatIgG2mayberelatedtoaTh1typeof
immunity. For instance, Gag-speciﬁc IgG2 levels correlated with
gamma interferon (IFN-) production (36). Different systemic
effects of full-length ﬂagellin and ﬂagellin with a truncated vari-
able region have been reported previously upon systemic or mu-
cosalimmunization,buttheunderlyingmechanismsarenotclear
(23). Studies with fusion proteins indicated that physical associa-
tion of ﬂagellin with antigens is necessary for ﬂagellin to promote
FIG5 Mucosalresponses.ChimericVLPsinduceenhancedmucosalimmune
responses measured at 18 weeks (A and B) or 38 weeks (C and D) in vaginal
washes. The ﬁnal dilutions of the vaginal secretion were 5-fold in panel A
(S-IgA),40-foldinpanelB(IgG),7-foldinpanelC(S-IgA),and150-foldin
panel D (IgG). Env-speciﬁc S-IgA and IgG were detected by ELISA and
expressed as mean OD450  standard deviation (SD). Asterisks and triangles
indicate statistically signiﬁcant differences between two cVLP groups
(P  0.05 by Student’s t test). (E) Neutralization of HXB2 pseudovirus. Vagi-
nal washes from i.n.-immunized guinea pigs were diluted 10-fold for the neu-
tralization assay. The infected cells were detected by -galactosidase expres-
sion.
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showedthatsolubleﬂagellinhasnoadjuvanteffectbyi.m.immu-
nization and has a low adjuvant effect by i.n. immunization when
mixed with VLP antigens. Although the exact mechanisms in-
volved in the different adjuvant effects of the bound and soluble
ﬂagellins are not completely understood, a different association
pattern of ﬂagellin with antigen could contribute to its ability to
function as an adjuvant. For cVLPs, incorporated ﬂagellin can
bind to surface TLR5 on APCs and thus facilitate VLP uptake and
consequent antigen processing and presentation. In contrast, if
coadministered with VLPs as a mixture, ﬂagellin and VLPs may
interactwithdifferentAPCs.Furthermore,independentofTLR5,
a member of the NOD-like receptor (NLR) family, Ipaf, has been
found to detect intracellular ﬂagellin and initiate innate signaling
by caspase 1 activation (37). VLPs are similar in their structure to
viruseswhichtheimmunesystemhasevolvedtocombatandthus
can be taken up directly by APCs (38). Consequently, ﬂagellin
incorporatedintocVLPsmayalsobesensedbyitscytosolicrecep-
tor for independent innate signaling. In contrast, soluble ﬂagellin
mixed with VLP antigens cannot be transported into the cytosol
without the help of bacterial virulence factors (39). These differ-
ences in interactions with the dual sensors for cVLPs containing
ﬂagellin may explain why the VLP-bound molecules are more
effectiveintranslatinginnateimmunesignalingintoadaptiveim-
munity.
It is of particular interest that HIV cVLPs incorporating
membrane-anchored truncated ﬂagellin induced enhanced mu-
cosal antibody responses. Mucosal transmission is the predomi-
nant pathway for HIV infection in humans, and the intestinal
mucosa is the major reservoir for virus replication and ampliﬁca-
tion (7). Effective HIV-speciﬁc mucosal antibody responses can
becapableofreducingtheoccurrenceofinitialinfectionandpos-
sibly blocking the escape of virus from the genital or intestinal
mucosa into systemic lymphoid organs (6, 7, 40). Recent studies
demonstrate that effective antibody even at low titer can block
repetitive low-dose SHIV infection, which simulates the natural
sexualtransmissionprocessofHIV(6).Althoughourresultsshow
that the IgA levels in mucosal samples are consistent with the
neutralizing activity, it has not been demonstrated that IgA is re-
sponsible for the increased neutralization capacity.
Most Env protein-based vaccine candidates are able to induce
Env-bindingIgGresponses,butwithoutenhancementofneutral-
ization(41).Thequalityofantibodyresponsesismoreimportant
than their quantity. The present data demonstrate that ﬂagellin-
containing cVLPs elicit broadened neutralization activity against
ﬁve strains from both clades B and C. Two characteristics of these
cVLPs may contribute to their ability to induce broadened neu-
tralizing activity: (i) HIV Env is presented by VLPs in its natural
trimeric structure in a membrane-bound microenvironment like
that of the native protein (42); (ii) the adjuvant effect of ﬂagellin
canenhanceHIV-speciﬁcadaptiveimmunity,inparticularbyin-
creasing the efﬁciency of antigen presentation of epitopes shared
by different subtypes. HIV cVLPs incorporating ﬂagellin as an
adjuvant therefore are promising as antigens for the development
of a prophylactic HIV vaccine.
MATERIALS AND METHODS
GenerationofrBVsexpressingmembrane-anchoredfull-lengthﬂagel-
lin(FliC)orFliCwithatruncatedvariableregion(tFliC).Toproducea
gene encoding the membrane-anchored FliC, the coding DNA sequences
forthemellitinsignalpeptide,full-lengthformofﬂagellin(ﬂiC;GenBank
accessionno.D13689[agiftfromAlanAderem]),andTM/CTdomainof
MMTVEnvwerefusedinframebyoverlappingPCR(12,24).Toproduce
themembrane-anchoredtFliC-encodinggene,theDNAfragmentcoding
the variable region (corresponding to aa 177 to 401 in the ﬂagellin pro-
tein) was deleted from the ﬂagellin gene, resulting in a gene encoding a
truncatedﬂagellin.ThecodingDNAsequencesofthemellitinsignalpep-
tide,truncatedﬂagellin,andTM/CTdomainofMMTVEnvwerefusedin
frame by overlapping PCR to generate the membrane-anchored tFliC-
encoding gene. The membrane-anchored FliC or tFliC gene was cloned
into pFastBac-1 (Invitrogen, Carlsbad, CA), and the integrity of these
genes was conﬁrmed by DNA sequencing. Recombinant BVs expressing
FliC or tFliC were generated by using the Bac-to-Bac insect cell protein
expression kit (Invitrogen) following the manufacturer’s instructions.
Production of standard or chimeric HIV VLPs. Standard HIV VLPs
(Env/Gag VLPs) were produced by coinfection of insect cells (Spodoptera
frugiperda Sf9 cells) with rBVs expressing Env and Gag as described pre-
viously (24). The cVLPs containing membrane-anchored FliC or tFliC
(Env/Gag/FliCorEnv/Gag/tFliCcVLPs)wereproducedbycoinfectionof
Sf9 cells with rBVs expressing Env, Gag, FliC, or tFlic. VLPs containing
GagonlyusedasacontrolwereproducedbyinfectionofSf9cellswithBVs
expressingGag.VLPswereconcentratedfromthesupernatantsofSf9cell
culture 62 to 70 h postinfection by porous ﬁber ﬁltration using the Quix-
stand benchtop system (GE Healthcare, Uppsala, Sweden) followed by
sucrosedensitygradientultracentrifugation,asdescribedpreviously(12),
and were characterized by protein assay, Western blotting, and sterility
assay. Amounts of incorporated Env and ﬂagellin were quantiﬁed by
Western blotting using corresponding puriﬁed recombinant proteins
as standards. The ﬁnal preparations of VLPs were normalized by Env
content.
Immunizationofguineapigsandsampling.Femaleguineapigswere
obtained from Charles River Laboratory (Wilmington, MA) and immu-
nized(fouranimalsineachgroup)fourtimeswithGag-onlyVLP(100g
total protein) or with Env-containing VLPs with doses containing 10 g
Env with or without incorporated ﬂagellin, or with a mixture of standard
VLPs (10 g Env) with soluble ﬂagellin (1.86 g sFliC as an average), by
theintramuscular(i.m.)orintranasal(i.n.)route.Asaverages,onedoseof
cVLP contained 1 to 2 g FliC. For i.n. immunization, VLPs in 100 l
phosphate-buffered saline (PBS) were instilled into each nostril (50 l
plus50l)ofguineapigslightlyanesthetizedwithketamine.Fourimmu-
nizations were performed at weeks 0, 4, 8, and 30. Serum samples were
collected at weeks 0 (preimmune bleeding), 2 (bleed 1), 6 (bleed 2), 10
(bleed 3), 30 (bleed 4), and 43 (bleed 5) by vena cava bleeding of anesthe-
tized guinea pigs. To collect vaginal samples, guinea pigs were anesthe-
tized, and the vaginal membranes were wiped with medical swabs. Pre-
weighedmedicalcottonQ-tipswereinsertedintothegenitaltractandleft
for 30 min and then weighed and extracted with PBS plus 0.02% Tween
20.Sampleswerestoredat80°C.Vaginalsampleswerecollectedatweek
18 (10 weeks after the third immunization) and 38 (8 weeks after the last
boost).
Serum and mucosal ELISA endpoint titers. Histidine-tagged Con-S
Env gp120 protein was puriﬁed from supernatants of HeLa cells infected
witharecombinantvacciniavirusexpressingthisprotein,asdescribedby
Blasco and Moss (43), using a nickel bead column. The Env-speciﬁc an-
tibody endpoint titers, including serum IgG and its subtypes (IgG1 and
IgG2) and mucosal IgA and IgG, were determined by enzyme-linked im-
munosorbentassay(ELISA)asdescribedpreviously(44).Inbrief,96-well
microtiter plates (Nunc-Immuno Plate Maxisorp; Nunc Life Technolo-
gies, Basel, Switzerland) were coated with 100 l/well of recombinant
Con-SEnvgp120protein(5g/ml)inacarbonatecoatingbuffer(pH9.2)
overnightat4°C.Theserumandmucosalsampleswereseriallydilutedin
2-foldsteps.Afterwashingandblockingwith1.5%bovineserumalbumin
(BSA), plates were used for assay of antibody binding with the diluted
samples. The detection color was developed by binding horseradish per-
oxidase (HRP)-labeled goat anti-guinea pig IgG, IgG1, IgG2, or IgA anti-
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ylbenzidine (TMB; Zymed, Invitrogen) was added. The optical density at
450 nm (OD450) was read with an ELISA reader (model 680; Bio-Rad).
The highest dilution which gave an OD450 2 times higher than that of the
naive group without dilution was designated as the antibody endpoint
titer.
Antibodyneutralizationassays.Serumsampleswereheatinactivated
at 56°C for 30 min, followed by neutralization assays. Neutralization was
performedwithahighlysensitive,single-roundinfectivityassaywithEnv-
pseudotyped virions (45–48). Neutralization activity is measured as the
percentage of reduction of viral infectivity in comparison to that in con-
trol wells infected with virus alone. The optical density reading in the
control well is indicative of the number of cells being productively in-
fected with virus. A reduction in luciferase production in wells infected
with virus preincubated with plasma indicates neutralization activity.
ACKNOWLEDGMENTS
ThisstudywassupportedbygrantsfromtheNationalInstitutesofHealth
(AI077406 and AI090840) and a pilot grant from the Yerkes National
Primate Research Center (P51RR000165-50).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
We thank Erin-Joi Collins for valuable assistance with manuscript
preparation and submission.
B.-Z.W., J.B., R.W.C., and Emory University have equity interests in
ZetraBiologicals,whichisdevelopingvirus-likeparticletechnologyunder
license from Emory University.
REFERENCES
1. Sodora, D. L., J. S. Allan, C. Apetrei, J. M. Brenchley, D. C. Douek, J. G.
Else, J. D. Estes, B. H. Hahn, V. M. Hirsch, A. Kaur, F. Kirchhoff, M.
Muller-Trutwin, I. Pandrea, J. E. Schmitz, and G. Silvestri. 2009.
Toward an AIDS vaccine: lessons from natural simian immunodeﬁciency
virus infections of African nonhuman primate hosts. Nat. Med. 15:
861–865.
2. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J.
Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M.
Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D.
Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thong-
charoen, M. L. Robb, N. L. Michael, P. Kunasol, and J. H. Kim. 2009.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N. Engl. J. Med. 361:2209–2220.
3. Song, L., Z. Y. Sun, K. E. Coleman, M. B. Zwick, J. S. Gach, J. H. Wang,
E. L. Reinherz, G. Wagner, and M. Kim. 2009. Broadly neutralizing
anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the
membrane interface. Proc. Natl. Acad. Sci. U. S. A. 106:9057–9062.
4. Pantophlet, R., T. Wrin, L. A. Cavacini, J. E. Robinson, and D. R.
Burton. 2008. Neutralizing activity of antibodies to the V3 loop region of
HIV-1 gp120 relative to their epitope ﬁne speciﬁcity. Virology 381:
251–260.
5. Zwick, M. B., and D. R. Burton. 2007. HIV-1 neutralization: mecha-
nisms and relevance to vaccine design. Curr. HIV Res. 5:608–624.
6. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani,
W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009.
Effective, low-titer antibody protection against low-dose repeated muco-
sal SHIV challenge in macaques. Nat. Med. 15:951–954.
7. Ahlers, J. D., and I. M. Belyakov. 2009. Strategies for optimizing target-
ing and delivery of mucosal HIV vaccines. Eur. J. Immunol. 39:
2657–2669.
8. Hu, S. L., and L. Stamatatos. 2007. Prospects of HIV Env modiﬁcation as
an approach to HIV vaccine design. Curr. HIV Res. 5:507–513.
9. Manrique, M., P. A. Kozlowski, S. W. Wang, R. L. Wilson, E. Micewicz,
D. C. Monteﬁori, K. G. Mansﬁeld, A. Carville, and A. Aldovini. 2009.
Nasal DNA-MVA SIV vaccination provides more signiﬁcant protection
from progression to AIDS than a similar intramuscular vaccination. Mu-
cosal Immunol. 2:536–550.
10. Quan, F. S., G. Sailaja, I. Skountzou, C. Huang, A. Vzorov, R. W.
Compans, and S. M. Kang. 2007. Immunogenicity of virus-like particles
containing modiﬁed human immunodeﬁciency virus envelope proteins.
Vaccine 25:3841–3850.
11. Sailaja, G., I. Skountzou, F. S. Quan, R. W. Compans, and S. M. Kang.
2007. Human immunodeﬁciency virus-like particles activate multiple
types of immune cells. Virology 362:331–341.
12. Wang, B. Z., F. S. Quan, S. M. Kang, J. Bozja, I. Skountzou, and R. W.
Compans. 2008. Incorporation of membrane-anchored ﬂagellin into in-
ﬂuenza virus-like particles enhances the breadth of immune responses. J.
Virol. 82:11813–11823.
13. Doan, L. X., M. Li, C. Chen, and Q. Yao. 2005. Virus-like particles as
HIV-1 vaccines. Rev. Med. Virol. 15:75–88.
14. Yao, Q., V. Vuong, M. Li, and R. W. Compans. 2002. Intranasal
immunization with SIV virus-like particles (VLPs) elicits systemic and
mucosal immunity. Vaccine 20:2537–2545.
15. Smith, K. D., E. Andersen-Nissen, F. Hayashi, K. Strobe, M. A. Bergman,
S. L. Barrett, B. T. Cookson, and A. Aderem. 2003. Toll-like receptor 5
recognizes a conserved site on ﬂagellin required for protoﬁlament formation
and bacterial motility. Nat. Immunol. 4:1247–1253.
16. Mizel, S. B., A. N. Honko, M. A. Moors, P. S. Smith, and A. P. West.
2003.InductionofmacrophagenitricoxideproductionbyGram-negative
ﬂagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like
receptor 4 complexes. J. Immunol. 170:6217–6223.
17. Honko, A. N., N. Sriranganathan, C. J. Lees, and S. B. Mizel. 2006.
Flagellin is an effective adjuvant for immunization against lethal respira-
tory challenge with Yersinia pestis. Infect. Immun. 74:1113–1120.
18. Cuadros, C., F. J. Lopez-Hernandez, A. L. Dominguez, M. McClelland,
and J. Lustgarten. 2004. Flagellin fusion proteins as adjuvants or vaccines
induce speciﬁc immune responses. Infect. Immun. 72:2810–2816.
19. Cunningham, A. F., M. Khan, J. Ball, K. M. Toellner, K. Serre, E. Mohr,
andI.C.MacLennan.2004.ResponsestothesolubleﬂagellarproteinFliC
are Th2, while those to FliC on Salmonella are Th1. Eur. J. Immunol.
34:2986–2995.
20. Huleatt, J. W., A. R. Jacobs, J. Tang, P. Desai, E. B. Kopp, Y. Huang, L.
Song, V. Nakaar, and T. J. Powell. 2007. Vaccination with recombinant
fusionproteinsincorporatingToll-likereceptorligandsinducesrapidcel-
lular and humoral immunity. Vaccine 25:763–775.
21. McDonald, W. F., J. W. Huleatt, H. G. Foellmer, D. Hewitt, J. Tang, P.
Desai, A. Price, A. Jacobs, V. N. Takahashi, Y. Huang, V. Nakaar, L.
Alexopoulou, E. Fikrig, and T. J. Powell. 2007. A West Nile virus recom-
binant protein vaccine that coactivates innate and adaptive immunity. J.
Infect. Dis. 195:1607–1617.
22. Skountzou, I., M. D. Martin, B. Wang, L. Ye, D. Koutsonanos, W.
Weldon, J. Jacob, and R. W. Compans. 2009. Salmonella ﬂagellins are
potent adjuvants for intranasally administered whole inactivated inﬂu-
enza vaccine. Vaccine 28:4103–4112.
23. Nempont, C., D. Cayet, M. Rumbo, C. Bompard, V. Villeret, and J. C.
Sirard. 2008. Deletion of ﬂagellin’s hypervariable region abrogates
antibody-mediated neutralization and systemic activation of TLR5-
dependent immunity. J. Immunol. 181:2036–2043.
24. Wang, B. Z., W. Liu, S. M. Kang, M. Alam, C. Huang, L. Ye, Y. Sun, Y.
Li, D. L. Kothe, P. Pushko, T. Dokland, B. F. Haynes, G. Smith, B. H.
Hahn, and R. W. Compans. 2007. Incorporation of high levels of chi-
meric human immunodeﬁciency virus envelope glycoproteins into virus-
like particles. J. Virol. 81:10869–10878.
25. Liao, H. X., L. L. Sutherland, S. M. Xia, M. E. Brock, R. M. Scearce, S.
Vanleeuwen, S. M. Alam, M. McAdams, E. A. Weaver, Z. Camacho,
B. J. Ma, Y. Li, J. M. Decker, G. J. Nabel, D. C. Monteﬁori, B. H. Hahn,
B. T. Korber, F. Gao, and B. F. Haynes. 2006. A group M consensus
envelope glycoprotein induces antibodies that neutralize subsets of sub-
type B and C HIV-1 primary viruses. Virology 353:268–282.
26. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson,
and M. A. Martin. 1986. Production of acquired immunodeﬁciency
syndrome-associated retrovirus in human and nonhuman cells trans-
fected with an infectious molecular clone. J. Virol. 59:284–291.
27. Binley, J. M., E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L.
Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C.
Nathe, D. Richman, G. D. Tomaras, F. Bibollet-Ruche, J. E. Robinson,
L. Morris, G. M. Shaw, D. C. Monteﬁori, and J. R. Mascola. 2008.
Proﬁling the speciﬁcity of neutralizing antibodies in a large panel of plas-
mas from patients chronically infected with human immunodeﬁciency
virus type 1 subtypes B and C. J. Virol. 82:11651–11668.
28. Li, Y., H. Hui, C. J. Burgess, R. W. Price, P. M. Sharp, B. H. Hahn, and
G. M. Shaw. 1992. Complete nucleotide sequence, genome organization,
and biological properties of human immunodeﬁciency virus type 1 in
Enhancing Immune Responses to HIV VLPs
January/February 2011 Volume 2 Issue 1 e00328-10
® mbio.asm.org 7vivo: evidence for limited defectiveness and complementation. J. Virol.
66:6587–6600.
29. Fujihashi, K., T. Koga, F. W. van Ginkel, Y. Hagiwara, and J. R.
McGhee. 2002. A dilemma for mucosal vaccination: efﬁcacy versus toxic-
ity using enterotoxin-based adjuvants. Vaccine 20:2431–2438.
30. Mestecky, J., S. M. Michalek, Z. Moldoveanu, and M. W. Russell. 1997.
Routesofimmunizationandantigendeliverysystemsforoptimalmucosal
immune responses in humans. Behring Inst. Mitt. 98:33–43.
31. Ben-Yedidia, T., and R. Arnon. 1998. Effect of pre-existing carrier im-
munity on the efﬁcacy of synthetic inﬂuenza vaccine. Immunol. Lett. 64:
9–15.
32. Kang, S. M., Q. Yao, L. Guo, and R. W. Compans. 2003. Mucosal
immunizationwithvirus-likeparticlesofsimianimmunodeﬁciencyvirus
conjugated with cholera toxin subunit B. J. Virol. 77:9823–9830.
33. McSorley, S. J., B. D. Ehst, Y. Yu, and A. T. Gewirtz. 2002. Bacterial
ﬂagellin is an effective adjuvant for CD4 T cells in vivo. J. Immunol.
169:3914–3919.
34. Singh, M., and D. O’Hagan. 1999. Advances in vaccine adjuvants. Nat.
Biotechnol. 17:1075–1081.
35. LeBien, T. W., and T. F. Tedder. 2008. B lymphocytes: how they develop
and function. Blood 112:1570–1580.
36. Kawahara, M. 2008. Recombinant Mycobacterium bovis BCG vector sys-
tem expressing SIV Gag protein stably and persistently induces antigen-
speciﬁc humoral immune response concomitant with IFN gamma re-
sponse, even at three years after immunization. Clin. Immunol. 129:
492–498.
37. Miao, E. A., E. Andersen-Nissen, S. E. Warren, and A. Aderem. 2007.
TLR5 and Ipaf: dual sensors of bacterial ﬂagellin in the innate immune
system. Semin. Immunopathol. 29:275–288.
38. Vyas, S. P., and P. N. Gupta. 2007. Implication of nanoparticles/
microparticles in mucosal vaccine delivery. Expert Rev. Vaccines
6:401–418.
39. Sun, Y. H., H. G. Rolan, and R. M. Tsolis. 2007. Injection of ﬂagellin into
thehostcellcytosolbySalmonellaentericaserotypeTyphimurium.J.Biol.
Chem. 282:33897–33901.
40. Kozlowski, P. A., and M. R. Neutra. 2003. The role of mucosal immunity
in prevention of HIV transmission. Curr. Mol. Med. 3:217–228.
41. Haynes, B. F., and D. C. Monteﬁori. 2006. Aiming to induce broadly
reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Expert Rev. Vaccines 5:579–595.
42. Crooks, E. T., P. L. Moore, M. Franti, C. S. Cayanan, P. Zhu, P. Jiang,
R. P. de Vries, C. Wiley, I. Zharkikh, N. Schulke, K. H. Roux, D. C.
Monteﬁori, D. R. Burton, and J. M. Binley. 2007. A comparative immu-
nogenicity study of HIV-1 virus-like particles bearing various forms of
envelope proteins, particles bearing no envelope and soluble monomeric
gp120. Virology 366:245–262.
43. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses
on the basis of plaque formation. Gene 158:157–162.
44. Quan, F. S., C. Huang, R. W. Compans, and S. M. Kang. 2007.
Virus-like particle vaccine induces protective immunity against homolo-
gous and heterologous strains of inﬂuenza virus. J. Virol. 81:3514–3524.
45. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O’Brien, L.
Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of
human immunodeﬁciency virus type 1 to the fusion inhibitor T-20 is
modulated by coreceptor speciﬁcity deﬁned by the V3 loop of gp120. J.
Virol. 74:8358–8367.
46. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F.
Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Kom-
arova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003.
Antibody neutralization and escape by HIV-1. Nature 422:307–312.
47. Monteﬁori, D. C. 2009. Measuring HIV neutralization in a luciferase
reporter gene assay. Methods Mol. Biol. 485:395–405.
48. Monteﬁori, D. C. 2005. Unit 12.11. Evaluating neutralizing antibodies
against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Pro-
toc. Immunol. doi:10.1002/0471142735.im1211s64.
Vassilieva et al.
8
® mbio.asm.org January/February 2011 Volume 2 Issue 1 e00328-10